Big Pharma Johnson &Johnson's to roll out its single-shot Covid Vaccine in India by the next month. Besides, it is being manufactured at 'Biological E' in Hyderabad. However, the officials have received Emergency Use Approval (EUA) from DCGI. Moreover, Vaccine batches will be sent to Central Drugs Laboratory (CDL) and National Centre for Cell Science (NCCS) for final testing by next week.
Courtesy: News 18
According to the statement given by the US-based pharmaceutical company, Johnson & Johnson notified that it has looked into the approval of the Central Drugs Standard Control Organisation to conduct a study on its Covid-19 vaccine for adolescents between 12-17 years old in India. Being “imperative”, all the nationals including children should be vaccinated against Covid-19 sooner. Besides, their vaccine is 85% effective in presenting… read-more
Courtesy: Zee News
Johnson & Johnson’s single-shot Covid-19 vaccine has been approved for emergency use by India on August 7 amid the growing fear of the upcoming third wave. Health Minister took to Twitter saying, “India expands its vaccine basket! Johnson and Johnson's single-dose Covid-19 vaccine is given approval for Emergency Use in India.” However, the date of arrival of the doses has not been confirmed yet.
Courtesy: The Khaleej Times
US-based pharmaceutical company Johnson & Johnson (J&J) to likely launch a single-dose vaccine against COVID-19 for emergency use in India. Reportedly, the government is yet to approve the proposal. The company also said they aim to launch the vaccine in collaboration with Hyderabad-based Biological E Limited. Notably, the vaccine's phase three clinical trial shows an efficiency of 85% against the Covid-19 strain.
A group of 15 US state attorneys general negotiated a settlement deal from large drug companies for $26 billion for allegedly distributing addictive drugs and opioids. The deal became the second-largest cash settlement ever, after the $246 billion tobacco agreement in 1998. Under the deal, the three largest US drug distributors, McKesson Corp, Cardinal Health Inc, and AmerisourceBergen Corp would pay a combined $21bn, while Johnson &… read-more
Courtesy: The Guardian
Johnson & Johnson (J&J) on July 14 said it will recall five of its sunscreen products after benzene, a cancer-causing agent, was detected in its samples. "We voluntarily decided to recall them out of an abundance of caution," J&J said in a statement. Investigations are underway to find out how these chemicals were used in the products. Meanwhile, J&J has requested to stop the usage of the five sunscreens immediately.
Courtesy: ABC NEWS
India’s principal scientific advisor and co-chair of COVID-19 vaccine task force, K Vijay Raghavan has expected that Centre will soon approve the Johnson and Johnson’s COVID vaccine. Assuring that the pricing and availability will be made transparent, Raghavan hoped the vaccine’s capacity to increases exponentially as Centre looks to boost manufacturing and export of vaccines. J&J recently applied to conduct phase-III clinical trials of… read-more
Courtesy: The Economic Times
World’s only single-shot COVID-19 vaccine, manufactured by Johnson & Johnson, will soon undergo clinical trials in India. Reportedly, J&J have sought permission from CDSCO (Central Drugs Standard Control Organisation) to start bridging clinical trials with a small number of participants. Moreover, it has partnered with Biological E to broaden its manufacturing in India. Notably, the bridging trials prove only the safety and… read-more
Courtesy: The Indian Express
Johnson & Johnson's clinical trials for a COVID-19 vaccine have been halted after an illness reported by one of the participants of the trial. Though the company has not revealed the exact nature of the illness, it has said that the illness is being reviewed by an independent board and their physicians. Experts opine that such incidents are common during the trials of a vaccine.
Few volunteers in 'Johnson & Johnson COVID-19 Vaccine trial' have dropped out citing adverse effects reported during Oxford's vaccine trial. Speaking in an interview, Alberto Borobia, the lead investigator, said that few volunteers from Spain have walked out and few others have been concerned about the risk and fear that the 'Oxford incident' could get repeated. However, he confirmed that they had enough volunteers to continue the trials… read-more
Courtesy: The Economic Times